Lineage Cell Therapeutics (FRA:BT3) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BT3 Lineage Cell Therapeutics Inc FRA:BT3
78 GF Score
Price €1.04
GF Value €1.17
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Lineage Cell Therapeutics Valuation Rank Related Terms

FRA:BT3
78GF Score
Lineage Cell Therapeutics Inc FRA:BT3
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lineage Cell Therapeutics (FRA:BT3) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of €1.04 is trading 11.5% below its estimated GF Value™ of €1.17.

Key valuation signals for FRA:BT3:

  • Valuation Rank:
  • GF Value™: €1.17 vs. price of €1.04 (11.5% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the FRA:BT3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for FRA:BT3

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price
€1.17
GF Value